Waters Corporation received FDA 510(k) clearance for an at-home HPV self-collection kit designed to work with the company's Onclarity HPV assay, the company announced April 8.
The clearance extends Waters' Onclarity platform beyond clinician-collected specimens. The self-collection kit allows patients to obtain vaginal samples at home, which are then sent to a laboratory for analysis with the Onclarity assay, according to Healthcare Packaging. Waters is historically known for analytical instrumentation including liquid chromatography and mass spectrometry systems.
The move places Waters in competition with established HPV testing platforms from Roche and Hologic as clinical guidelines and payer policies evolve toward patient-initiated screening. Self-collection has been viewed by public health officials as a strategy to improve cervical cancer screening rates, particularly among underserved populations.
Commercial adoption will depend on reimbursement. A 510(k) clearance establishes substantial equivalence to a predicate device but does not guarantee payer coverage for at-home specimen collection. Waters will need to secure coding and coverage agreements with Medicare and private insurers. The company has not disclosed sensitivity or specificity data from the 510(k) submission, making direct performance comparisons to competing assays difficult.
The clearance comes as the diagnostics sector faces both consolidation and clinical setbacks. GRAIL's multicancer early detection test missed its primary endpoint in the NHS-Galleri trial this week, and bioMérieux announced a $450 million acquisition of BioFire on the same day as Waters' clearance.